AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain)...
LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), (the ''Company'' or ''CLS''), a...
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...
Pricing Provides AmnioWrap2™ Reimbursement in All MAC Regions We Manufacture Products That Change Lives We Manufacture Products That Change Lives POMPANO...
HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment...
Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer to Propel Innovations in Complex Multisystem Disorder CareSALT...
Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer to Propel Innovations in Complex Multisystem Disorder CareSALT...
POMPANO BEACH, Fla., Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on...
Reports filing of Restated Q3 2023 Financial Statements and Restated 2022 Audited Consolidated Financial StatementsThird Quarter HighlightsNet Loss of $5.4...
Preventogen's FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and...
SAN DIEGO, CA / ACCESSWIRE / December 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos," or the "Company"), a diversified...
Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners....
CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to...
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,...
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 /...
CHICAGO, IL / ACCESSWIRE / December 7, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology...
122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology...
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to...